Quick Answer
Maze Therapeutics, Inc. reported Stockholders Equity of $354.97 million for the year ending 2025.
- Maze Therapeutics, Inc. showed an increase of +214.1% in Stockholders Equity from 2024 to 2025.
- This data is from Maze Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2025: $292.07 million | Q2 2025: $262.24 million | Q3 2025: $379.44 million.
- Historical annual values: Fiscal year 2025: $354.97 million | Fiscal year 2024: -$311.18 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: